Multiple Myeloma Face-off: Ravi Vij, MD, MBA Discusses Readout of ASH 2022 Data

As part of its Face-Off video series, CancerNetwork spoke with Ravi Vij, MD, MBA, from Washington University School of Medicine.

EP. 1: SWOG S0777 Trial Proves VRd To Be Viable Option for Untreated Myeloma That Is Unintended for ASCT

December 20th 2022

Ravi Vij, MD, MBA, discussed updated analyses of the phase 3 SWOG S0777 trial, supporting the use of bortezomib, lenalidomide, and dexamethasone in untreated patients with multiple myeloma who do not plan on receiving immediate autologous stem cell transplant.

EP. 2: Expert Offers Considerations For Frontline Combination Therapies in Multiple Myeloma

December 20th 2022

Ravi Vij, MD, MBA, offered additional information about the use of various regimens aimed to treat patients with high-risk, newly diagnosed multiple myeloma, that were read out at the 2022 ASH Annual Meeting.

EP. 3: Ongoing Trials May Pave Way To Bring Later-Line Therapies Upfront in Newly Diagnosed Multiple Myeloma

December 20th 2022

Ravi Vij, MD, MBA, suggested that 4-drug regimens may be a new standard for frontline therapy in newly diagnosed multiple myeloma, as oncologists await trial readouts from ongoing clinical trials.